Prognostic nomograms to predict oncological outcome of thyroid cancers

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 12, 2013, Pages 4768-4775

  Pathak, K Alok ^a,b   Mazurat, Andrea ^b   Lambert, Pascal ^a   Klonisch, Thomas ^b   Nason, Richard W ^a,b  

^a CANCERCARE MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; PROPYLTHIOURACIL; THIAMAZOLE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGRANULOCYTOSIS; ARTICLE; BIOSTATISTICS; CHILD; CONTROLLED STUDY; DATA BASE; DISEASE COURSE; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FATALITY; FEMALE; GRANULOCYTE; GRAVES DISEASE; HEALTH INSURANCE; HOSPITAL PATIENT; HUMAN; HUMAN CELL; INCIDENCE; JAPAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PANCYTOPENIA; PRIORITY JOURNAL; SCHOOL CHILD; SEX DIFFERENCE; SEX RATIO; URTICARIA; VERY ELDERLY; YOUNG ADULT;

ADULT; CANCER CARE FACILITIES; CARCINOMA; CARCINOMA, PAPILLARY; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LYMPHATIC METASTASIS; MALE; MANITOBA; MODELS, BIOLOGICAL; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROGNOSIS; RISK; SURVIVAL ANALYSIS; THYROID NEOPLASMS;

EID: 84889798809     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2318     Document Type: Article

References (40)

1. Canadian Cancer Society Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2012. Toronto, ON, Canada: Canadian Cancer Society; 2012:7-60
2. Ellison LF, Wilkins K. An update on cancer survival. Health Rep. 2010;21:55-60
3. Canadian Cancer Society Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2011. Toronto, ON, Canada: Canadian Cancer Society; 2011:25-60
4. Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer. 1979;15:1033-1041
5. Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroid carcinoma treatment: Initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer. 1998;83:1012-1021
6. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: A retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102:1088-1095
7. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947-953
8. Sobin L, Gospodarowicz M, Wittekind C. TNM Classification of Malignant Tumours. 7th ed. New York, NY: John Wiley; 2009:58- 62
9. Yildirim E. A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systems. J Am Coll Surg. 2005;200:378- 392
10. Pasieka JL, Zedenius J, Auer G, et al. Addition of nuclear DNA content to the AMES risk-group classification for papillary thyroid cancer. Surgery. 1992;112:1154-1159; discussion 1159-1160
11. Akslen LA. Prognostic importance of histologic grading in papillary thyroid carcinoma. Cancer. 1993;72:2680-2685
12. DeGroot LJ, Kaplan EL,McCormickM,Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71:414-424
13. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients sur-gically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050-1057; discussion 1057-1058
14. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418-428
15. Noguchi S, Murakami N, Kawamoto H. Classification of papillary cancer of the thyroid based on prognosis. World J Surg. 1994;18: 552-557
16. Shaha AR, Loree TR, Shah JP. Intermediate-risk group for differentiated carcinoma of thyroid. Surgery. 1994;116:1036-1040; discussion 1040-1041
17. Sebastian SO, Gonzalez JM, Paricio PP, et al. Papillary thyroid carcinoma: Prognostic index for survival including the histological variety. Arch Surg. 2000;135:272-277
18. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. A novel classification system for patients with PTC: Addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery. 2004;135:139-148
19. Kattan MW, Yu C, Salomon L, Vora K, Touijer K, Guillonneau B. Development and validation of preoperative nomogram for disease recurrence within 5 years after laparoscopic radical prostatectomy for prostate cancer. Urology. 2011;77:396-401
20. Lachance JA, Choudhri AF, Sarti M, Modesitt SC, Jazaeri AA, Stukenborg GJ. A nomogram for estimating the probability of ovarian cancer. Gynecol Oncol. 2011;121:2-7
21. Klar M, Jochmann A, Foeldi M, et al. The MSKCC nomogram for prediction the likelihood of non-sentinel node involvement in a German breast cancer population. Breast Cancer Res Treat. 2008;112: 523-531
22. Mariani L, Miceli R, Kattan MW, et al. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer. 2005;103: 402-408
23. Eilber FC, Brennan MF, Eilber FR, Dry SM, Singer S, Kattan MW. Validation of the postoperative nomogram for 12-year sarcomaspecific mortality. Cancer. 2004;101:2270-2275
24. Peeters KC, Kattan MW, Hartgrink HH, et al. Validation of a nomogram for predicting disease-specific survival after anR0resection for gastric carcinoma. Cancer. 2005;103:702-707
25. Hoang T,XuR, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaive patients with advanced non-smallcell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol. 2005;23:175-183
26. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperativenomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol. 2003;21:3647-3650
27. Brennan MF, Kattan MW, Klimstra D, Conlon K. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg. 2004;240:293-298
28. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol. 2005;173:48-51
29. Yang L, Shen W, Sakamoto N. Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer. J Clin Oncol. 2013;31:468-474
30. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154
31. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509
32. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26: 1364-1370
33. RomanS, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107:2134-2142
34. Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: Analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid. 1996;6:305-310
35. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214
36. Gorlin JB, Sallan SE. Thyroid cancer in childhood. Endocrinol Metab Clin North Am. 1990;19:649-662
37. Pathak KA, LeslieWD,Klonisch TC, NasonRW.The changing face of thyroid cancer in a population based cohort. Cancer Med. doi: 10.1002/cam4.103
38. Wang TS, Sosa JA. Thyroid gland: Can a nomogram predict death in patients with thyroid cancer? Nat Rev Endocrinol. 2013;9:192- 193
39. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387
40. Wolbers M, Koller MT, Witteman JC, Steyerberg EW. Prognostic models with competing risks: methods and application to coronary risk prediction. Epidemiology. 2009;20:555-561